March 19, 2021 07:20 AM EDTUpdated 07:41 AM

Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch

Amber Tong

Jakafi disappointed Incyte once when it failed to prevent severe complications of Covid-19. The JAK inhibitor has fallen short again in another Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch

Amber Tong

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Jakafi failed the pri­ma­ry end­point in a Covid-19 study. But In­cyte is still go­ing to FDA with a com­pas­sion­ate use pitch

Amber Tong

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?